Navigation Links
ViroPharma and Halozyme Therapeutics Announce Positive Data From Initial Phase 2 Assessment of Subcutaneous Cinryze® (C1 esterase inhibitor [human]) with Hyaluronidase (rHuPH20)
Date:12/6/2011

andidates in its pipeline that target multiple areas of significant unmet medical need. For more information visit www.halozyme.com.

ViroPharma Forward Looking Statements

Certain statements in this press release contain forward-looking statements that involve a number of risks and uncertainties. Forward-looking statements provide our current expectations or forecasts of future events, including the therapeutic indication and use, safety, efficacy, tolerability and potential of Cinryze and our focus, goals, strategy, research and development programs, and ability to develop pharmaceutical products, commercialize pharmaceutical products, and execute on our plans including clinical development activities with Cinryze related to subcutaneous administration.

The safety, pharmacokinetics and pharmacodynamics data described in this press release are preliminary and additional review of the data may reveal additional findings which may not be consistent with this press release. The data described in this press release may not be predictive of the results of future studies and there can be no assurance that that future studies with Cinryze utilizing subcutaneous administration in combination with rHuPH20 will yield positive results or support further development of Cinryze for subcutaneous administration in combination with rHuPH20. The FDA or EMA may view the data regarding subcutaneous administration of Cinryze in combination with rHuPH20 as insufficient or inconclusive, request additional data, require additional clinical studies, delay any decision past the time frames anticipated by us, limit any approved indications, or deny the approval of Cinryze for subcutaneous administration in combination with rHuPH20. These factors, and other factors, including, but not limited to those described in our annual report on Form 10-K for the year ended December 31, 2010 and quarterly reports on Form 10-Q filed wit
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. ViroPharma to Participate in Two November Healthcare Investor Conferences
2. ViroPharma to Acquire DuoCort Pharma AB, Adding Important European Orphan Drug to Commercial Pipeline
3. ViroPharma Incorporated Reports Third Quarter 2011 Financial Results
4. ViroPharma to Release 2011 Third Quarter Financial Results on October 27, 2011
5. ViroPharma Licenses Rights From Intellect Neurosciences for Product Candidate for Friedreichs Ataxia
6. ViroPharma Announces Additional Securities Repurchase Program
7. ViroPharma and Halozyme Therapeutics Announce Initiation of Phase 2 Evaluation of Subcutaneous Delivery of Cinryze® (C1 Esterase Inhibitor [Human]) with Hyaluronidase (rHuPH20)
8. ViroPharmas Buccolam® (Midazolam, Oromucosal Solution) Granted European Marketing Authorization for Treatment of Acute Seizures
9. ViroPharma to Participate in the Stifel Nicolaus 2011 Healthcare Conference
10. ViroPharma Announces Positive CHMP Opinion for Buccolam® (Midazolam, Oromucosal Solution) in the European Union
11. ViroPharmas Cinryze® (C1 Inhibitor [Human]) Granted European Marketing Authorization for Hereditary Angioedema (HAE)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/1/2015)... 2015 LifeScienceIndustryResearch.com announces ... Industry and 2015 Deep Research Report on ... Pharmaceutical category in its database.  ... basic information, including definition, classification, application, industry ... news analysis, etc. Azithromycin Key Manufacturers Analysis ...
(Date:4/1/2015)... -- Jintian Pharmaceutical Group Limited ("Jintian Pharmaceutical" or the ... chairman and executive director purchased 40,000,000 ordinary shares (the ... entire issued share capital of the Company from AMG ... amount of approximately HK$113 million. Upon the completion of ... 45.17% to 47.17%. Mr. Jin Dongtao, ...
(Date:4/1/2015)... and Markets ( http://www.researchandmarkets.com/research/n9mxqs/an_introduction ) has announced ... Medical Device Directives" conference to their offering. ... European medical device legislation. It will explain the Directives ... Bodies, how to choose one and outline what a ... necessary to apply for the CE mark. ...
Breaking Medicine Technology:Azithromycin Market & Polypeptide Drug Industry - Global Research Reports 2Azithromycin Market & Polypeptide Drug Industry - Global Research Reports 3Azithromycin Market & Polypeptide Drug Industry - Global Research Reports 4Azithromycin Market & Polypeptide Drug Industry - Global Research Reports 5Chairman of Jintian Pharmaceutical Purchased Approximately HK$113 Million Worth of Shares Citing Confidence in Company's Development in Online and Offline MacroHealth Business 2Chairman of Jintian Pharmaceutical Purchased Approximately HK$113 Million Worth of Shares Citing Confidence in Company's Development in Online and Offline MacroHealth Business 3Chairman of Jintian Pharmaceutical Purchased Approximately HK$113 Million Worth of Shares Citing Confidence in Company's Development in Online and Offline MacroHealth Business 4Chairman of Jintian Pharmaceutical Purchased Approximately HK$113 Million Worth of Shares Citing Confidence in Company's Development in Online and Offline MacroHealth Business 5An Introduction to the Medical Device Directives Training: London, UK - 13th, 14th, 15th of May 2015 2
... Labs, Inc. (OTCQB/OTCBB: GOVX), an Atlanta-based biopharmaceutical firm developing ... infections, announced today the completion of enrollment for a ... vaccine is being developed for use in uninfected people ... virus. The trial, designated HVTN 205, is being conducted ...
... Inc. (NASDAQ: VVUS ) today announced that ... th Annual Scientific Meeting of The Obesity Society ... long-term beneficial effects of Qnexa ® treatment in ... significant improvement in liver function and reductions in medications ...
Cached Medicine Technology:GeoVax Phase 2a Clinical Trial Completes Enrollment 2GeoVax Phase 2a Clinical Trial Completes Enrollment 3GeoVax Phase 2a Clinical Trial Completes Enrollment 4Two-year Treatment With Qnexa Has Benefits Beyond Weight Loss 2Two-year Treatment With Qnexa Has Benefits Beyond Weight Loss 3Two-year Treatment With Qnexa Has Benefits Beyond Weight Loss 4Two-year Treatment With Qnexa Has Benefits Beyond Weight Loss 5Two-year Treatment With Qnexa Has Benefits Beyond Weight Loss 6
(Date:4/1/2015)... 01, 2015 Tempaper has joined forces ... virtual giving campaign that will raise critical funds to ... muscle disease across the United States. , Throughout the ... Tempaperdesigns.com will automatically receive free domestic ground ... and urgently needed progress to children and adults affected ...
(Date:4/1/2015)... FL (PRWEB) April 01, 2015 IQ ... growing health and nutritional supplement companies in the U.S., today ... the testing and quality control standards for its herbal supplements.* ... the supply chain to ensure the accuracy of labeling on ... industry veteran and IQ Formulations CEO Jay Cohen ...
(Date:4/1/2015)... April 01, 2015 When annoying or ... waiting days or weeks for an appointment with a ... and next day appointments haven’t been possible within dermatology. ... Dermatology’s offices have noticed demand for this level of ... realize how important relief or answers to dermatological issues ...
(Date:4/1/2015)... The 2015 Deep Market Research ... professional and in-depth study on the current state ... with a focus on the Chinese situation. , ... are Pfizer, Lek Pharmaceuticals D.D., Dr Reddys Labs ... Limited, Cadila Healthcare Limited, Sandoz Inc, Teva Pharms, ...
(Date:4/1/2015)... New York, NY (PRWEB) April 01, 2015 ... currently reports there are “more than 123,000 patients who ... may not be aware of this surprising statistic. ... to Donate Life” PSA, Erik Compton, a PGA TOUR ... organ donation and encourages Americans to become organ donors. ...
Breaking Medicine News(10 mins):Health News:Tempaper and MDA Team up in the Fight Against Muscle Disease 2Health News:Tempaper and MDA Team up in the Fight Against Muscle Disease 3Health News:IQ Formulations Applauds GNC for Enhancing Its Testing and Quality Control Processes for Herbal Supplements 2Health News:Dermatology Associates of Wisconsin and Forefront Dermatology Answers Patients' Needs With Unmatched Availability In Sheboygan and Sheboygan Falls 2Health News:Atorvastatin Calcium Industry International & China Market Analysis 2015-2020 2Health News:Atorvastatin Calcium Industry International & China Market Analysis 2015-2020 3Health News:Donate Life America and Genentech have Partnered to Develop the “Play Through with Erik Compton to Donate Life" Public Service Announcement 2
... ... support to the Major League Baseball Players Alumni association to raise ... and auction, helps provide hope and funding for end stage cancer ... and life for cancer patients and their families. Providing financial assistance ...
... ... progress but says there are still too many preventable automobile accidents. , ... New York, NY (PRWEB) April 23, 2010 -- ... become complacent to driving hazards as they hit the highway for a summer vacation road ...
... Cancer is the number-one ... Buffalo are partnering to raise awareness and funds to fight this devastating disease. The goal this ... Foundation to fund research and finding a cure. , ... Wilton, Conn., and San Diego (PRWEB) April 24, 2010 -- Cancer is ...
... He Volunteered ... His Experience to Further the Search for a Cure and Better Treatments for PD. ... (PRWEB) -- “Deep Brain Diary: ... personal story about living with a neurological disease that afflicts over a million Americans. ...
... ... to grow enormously over the next few years and healthcare related jobs ... greater employment opportunities for those individuals educated and trained in any of ... generation will bring with it a strong demand for skilled medical workers, ...
... Groundbreaking move ... data.worldbank.org. , ... April 22, 2010 -- The World Bank Group announced on Tuesday that it has thrown ... to use the data to create new applications and solutions to help poor people in ...
Cached Medicine News:Health News:Major League Baseball Players Alumni Help Lazarex Cancer Foundation Raise Funds 2Health News:Major League Baseball Players Alumni Help Lazarex Cancer Foundation Raise Funds 3Health News:U.S. and New York Car Accident Deaths Continue Steady Decline 2Health News:BLUE Buffalo Pet Food and PETCO Partner to Fight Pet Cancer During Pet Cancer Awareness Month 2Health News:BLUE Buffalo Pet Food and PETCO Partner to Fight Pet Cancer During Pet Cancer Awareness Month 3Health News:BLUE Buffalo Pet Food and PETCO Partner to Fight Pet Cancer During Pet Cancer Awareness Month 4Health News:Parkinson's Disease Patient's Story Goes Multimedia, Proceeds to Benefit PD Research 2Health News:Parkinson's Disease Patient's Story Goes Multimedia, Proceeds to Benefit PD Research 3Health News:Parkinson's Disease Patient's Story Goes Multimedia, Proceeds to Benefit PD Research 4Health News:Prospective Healthcare Workers: Fully Accredited Healthcare Degree Programs Are Now Offered Through OnlineEducation.com 2Health News:Prospective Healthcare Workers: Fully Accredited Healthcare Degree Programs Are Now Offered Through OnlineEducation.com 3Health News:Prospective Healthcare Workers: Fully Accredited Healthcare Degree Programs Are Now Offered Through OnlineEducation.com 4Health News:Prospective Healthcare Workers: Fully Accredited Healthcare Degree Programs Are Now Offered Through OnlineEducation.com 5Health News:World Bank Group Opens Data to All 2
ZYMAR™ ophthalmic solution is an anti-infective prescription eye drop that your doctor may instruct you to use if you have an eye infection caused by bacteria. Bacterial conjunctivitis is the e...
... P.M.® lets you sleep on ... in the morning awake with ... ready to take on the ... comfort and protection, this preservative-free ...
Due to its thick formula, REFRESH CELLUVISC Lubricant Eye Drops is ideal for persistent dry eye conditions. REFRESH CELLUVISC provides lasting relief and protection for dry, scratchy eyes....
ALPHAGAN® (brimonidine tartrate ophthalmic solution) 0.2% is indicated for lowering IOP in patients with open-angle galucoma or ocular hypertension....
Medicine Products: